EVOTEC SE (EVT.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:EVT - DE0005664809 - Common Stock
EVT.DE Key Statistics, Chart & Performance
The current stock price of EVT.DE is 5.573 EUR. In the past month the price decreased by -6.02%. In the past year, price decreased by -37.65%.
EVT.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 49.74 | 20.87B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 49.88 | 20.93B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 56.71 | 19.36B | ||
| SRT.DE | SARTORIUS AG | 43.97 | 15.01B | ||
| QIA.DE | QIAGEN N.V. | 19.85 | 8.74B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 19.26 | 2.81B | ||
| GXI.DE | GERRESHEIMER AG | 7.19 | 916.69M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.51 | 206.26M |
Related stock screener links
About EVT.DE
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,759 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
EVOTEC SE
Essener Bogen 7
Hamburg HAMBURG DE
Employees: 4740
Phone: 4940560810
EVOTEC SE / EVT.DE FAQ
Can you describe the business of EVOTEC SE?
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,759 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Can you provide the latest stock price for EVOTEC SE?
The current stock price of EVT.DE is 5.573 EUR. The price increased by 1.92% in the last trading session.
Does EVOTEC SE pay dividends?
EVT.DE does not pay a dividend.
What is the ChartMill rating of EVOTEC SE stock?
EVT.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for EVT.DE stock?
13 analysts have analysed EVT.DE and the average price target is 9.23 EUR. This implies a price increase of 65.6% is expected in the next year compared to the current price of 5.573.
Is EVOTEC SE (EVT.DE) expected to grow?
The Revenue of EVOTEC SE (EVT.DE) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for EVOTEC SE?
EVOTEC SE (EVT.DE) has a market capitalization of 1.98B EUR. This makes EVT.DE a Small Cap stock.
EVT.DE Technical Analysis
EVT.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVT.DE. EVT.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EVT.DE Financial Highlights
Over the last trailing twelve months EVT.DE reported a non-GAAP Earnings per Share(EPS) of -1.11. The EPS decreased by -136.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| Debt/Equity | 0.48 |
EVT.DE Forecast & Estimates
13 analysts have analysed EVT.DE and the average price target is 9.23 EUR. This implies a price increase of 65.6% is expected in the next year compared to the current price of 5.573.
For the next year, analysts expect an EPS growth of 59.73% and a revenue growth -2.27% for EVT.DE